Key facts
- Spectral Medical and Vantive released 12-month follow-up results from the Tigris Trial.
- The Tigris Trial assessed the safety and efficacy of Spectral's endotoxin activity assay (EAA).
- The trial focused on patients experiencing septic shock.
Spectral Medical, a Toronto-based company, in collaboration with Vantive, has announced the topline 12-month follow-up results from its Tigris Trial. This clinical trial was designed to evaluate the safety and efficacy of Spectral's endotoxin activity assay (EAA). The study specifically focused on patients diagnosed with septic shock, a life-threatening condition caused by the body's response to infection.